- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
Type 1 diabetes

Type 1 diabetes occurs when the immune system attacks and destroys the beta cells in the pancreas that produce the hormone insulin. Without insulin, the level of the sugar glucose in the blood cannot be controlled.
Type 1 diabetes is a serious lifelong health condition. Our type 1 diabetes researchers are discovering how harmful immune responses damage the insulin-producing cells. This is leading to new ways to prevent and treat type 1 diabetes.
Our type 1 diabetes research
Our researchers are working to improve the prevention and treatment of type 1 diabetes. Their goals are to:
- Understand why immune cells attack insulin-producing cells.
- Understand the environmental factors that predispose to type 1 diabetes.
- Develop and trial new ways to prevent type 1 diabetes.
- Develop immune therapies to treat type 1 diabetes.
- Develop strategies to regenerate insulin-producing cells from stem cells as a cure for type 1 diabetes.
- Improve the success of pancreas transplantation as a cure for type 1 diabetes.
- Develop novel insulin analogues that will make life easier for patients with type 1 diabetes.
What is type 1 diabetes?
The amount of glucose in the blood is normally tightly controlled. But in diabetes blood glucose levels are abnormally high.
The hormone insulin normally reduces blood glucose levels and is produced by cells in the pancreas called ‘beta cells’. However, in type 1 diabetes there is a misdirected ‘autoimmune’ reaction to the insulin-producing beta cells in the pancreas, which leads to insufficient insulin being produced. Without insulin, high levels of glucose accumulate in the blood.
The immune system protects our body from invading microbes. There are normally many safeguards that prevent it from attacking the body’s own tissues. In type 1 diabetes, these safeguards fail, and immune cells specifically destroy beta cells.
Type 1 diabetes is the most common chronic (long-term) childhood illness in Australia. More than 120,000 Australians have type 1 diabetes. The incidence of type 1 diabetes in Australia has increased in the past 30 years.
Most people with type 1 diabetes are diagnosed as children or young adults. Even with a lifetime of the best available care, they are at increased risk of serious complications such as
- Kidney disease (diabetic nephropathy)
- Eye disease and blindness (diabetic retinopathy)
- Nerve damage (diabetic neuropathy)
- Damage to blood vessels, which together with nerve damage can lead to serious problems in the hands and feet
- Heart disease and stroke
Risk factors for type 1 diabetes
Type 1 diabetes is caused by a combination of genetic risk and environmental factors. Our researchers have shown that changes in our environment have contributed to the increase in the incidence of type 1 diabetes in the past few decades.
Many environmental factors have been proposed to trigger or promote type 1 diabetes. These include infections, diet and weight gain.
Known risk factors for type 1 diabetes include:
- Having other autoimmune or inflammatory diseases such as coeliac disease or autoimmune thyroid disease. These conditions all involve aberrant immune responses.
- Having a parent or sibling with type 1 diabetes or other autoimmune diseases. One in five Australians diagnosed with type 1 diabetes have a family history of the condition.
- Living at higher latitudes: the incidence of type 1 diabetes is increased in populations who live furthest from the equator. This may be partly genetic. It may also be related to environmental factors such as vitamin D deficiency and hygiene.
How is type 1 diabetes treated?
Almost all people with type 1 diabetes rely on insulin injections for their entire lives. They must closely monitor their blood glucose levels. When blood glucose rises, such as after a meal, an appropriate insulin dose is calculated and injected. Insulin is available in ‘slow acting’ and ‘fast acting’ forms. These can aid the smoother control of blood glucose levels.
There is no orally available (tablet) form of insulin. Insulin can only be given by injection, such as with a syringe. Recently, small, attachable insulin pumps have been introduced instead of multiple daily injections. Insulin pumps may control blood glucose better by providing a more steady release of insulin into the body.
The only cure for type 1 diabetes is transplantation or regeneration of insulin-producing cells.
Transplantation of the whole pancreas or the parts of the pancreas containing insulin-secreting beta cells can be performed. It is limited by a shortage of organ donors, and the need for life-long immune suppression to prevent transplant rejection. Thus, transplantation is restricted to people with poorly controlled diabetes and serious complications.
Our researchers have shown that the pancreas contains stem cells that can be transformed into beta cells. Their hope is that it may one day be possible to cure type 1 diabetes by stimulating the regrowth of beta cells. This would depend on stifling the immune cells that originally destroyed the beta cells.
Diabetes Australia has more detailed information about diabetes treatment.
Type 1 diabetes ‘vaccine’
Our research into how immune cells attack insulin-producing cells has led to a new strategy to prevent type 1 diabetes. A nasal insulin ‘vaccine’ developed by our researchers has shown promise in clinical trials for preventing the development of type 1 diabetes.
Researchers:
Super Content:
A five-year international trial has found that type 1 diabetes can be delayed by an immune therapy.
The therapy, teplizumab, delayed the onset of diabetes in participants by two years.
A drop in the number of young children diagnosed with type 1 diabetes could be associated with the introduction of routine rotavirus vaccination of Australian infants.
Australia's largest study into the causes of type 1 diabetes will track women and children from early pregnancy to three years of age.
A landmark discovery about how insulin docks on cells could help in the development of improved types of insulin for treating both type 1 and type 2 diabetes.